trans

486 INDEX
genome, 21
survey sequences (GSS), 10
host immune response, 104
innate resistance, 105
laboratory studies, 91
mitogen-activated protein (MAP) kinases, 268,
269, 270
phosphoglycerate kinase (PGK) posttranscriptional
regulation, 74–5
polyamines synthesis, 189, 190, 191
procyclins, see Procyclins
promoter structures, 52, 53
proteasome, 85, 177, 178, 180
protein phosphatases, 274
proteolytic enzymes, 174, 176, 177
proto-apoptosis, 227
purine metabolism, 204–5, 215
pyrimidine metabolism, 204–5, 221
RNA degradation, 78–80, 84
RNA editing, 38, 39, 43
RNA pol I, 56
RNA 3-untranslated regions, 78–80
spliced leader (SL) RNA gene promoter, 61
surface coat structure, 91
T. rhodesiense/T. gambiense genetic exchange, 105
telomeres, 100
transcription:
class I genes, 50–1
class II genes, 57
major cell surface antigens, 49–50
promoter DNA-protein interactions, 54–5
regulation, 51
termination, 55
U2 snRNA genes, 63
transferrin receptors, 101
translation control, 85
variant surface glycoproteins (VSGs), see Variant
surface glycoprotein (VSG)
VSG genes, 97, 102–3
Trypanosoma brucei brucei, 140
chemotherapy, 419
polyamines synthesis, 191
purine metabolism, 215
Trypanosoma brucei gambiense, 91, 104, 105, 140,
397, 437
chemotherapy, 418, 419, 420, 421, 448–50
clinical aspects, 448
drug resistance, 421
polyamines synthesis, 189
purine metabolism, 215
T. rhodesiense genetic exchange, 105
Trypanosoma brucei rhodesiense, 91, 104–5, 140,
397, 437
chemotherapy, 418, 419, 421, 448–50
clinical aspects, 448
drug resistance, 421
glucose transporters, 144
polyamines synthesis, 191
purine metabolism, 215
T. gambiense genetic exchange, 105
Trypanosoma congolense,91
chemotherapy, 419
proteolytic enzymes, 174, 176
variant surface glycoproteins (VSGs), 95, 96
Trypanosoma cruzi, 73, 74, 397, 437
acidocalcisomes, 249, 250
adenylyl cyclases, 259, 260
functional aspects, 262
amino acid metabolism, 188, 190, 191, 192
catabolism, 187
glutamate dehydrogenases, 182
transport, 173
Ca 2 metabolism, 247, 248, 250, 251
SERCA calcium pumps, 246
calcium signaling, 256
calcium-binding proteins, 251, 252, 253,
254
calreticulin, 245
chemotherapy, 422–3, 446–8
clinical aspects, 446–7
energy metabolism, 146
therapeutic targets, 146–7
genome, 20, 21
invasion processes, 256
lipopeptidophosphoglycan, 230–1
mitogen-activated protein (MAP) kinases,
268
promoter structures, 54
proteasome, 177, 180
protein phosphatases, 274
proteolytic enzymes, 174, 176, 177, 180
therapeutic targets, 181, 182
purine metabolism, 214–15
transport, 204
pyrimidine metabolism, 221
RNA degradation regulation, 77
RNA post-transcriptional regulation, 79, 81
SIRE transposable element, 76
surface mucins, 225, 228–30
function, 230
mucin genes, 79, 228
structure, 228–30